ASH 2018 | Isatuximab plus VRd for newly diagnosed transplant-ineligible myeloma

Enrique Ocio

In this interview, Enrique Ocio, MD, PhD, of the University Hospital of Salamanca, Salamanca, Spain, presents the initial data from a Phase Ib study (NCT02513186) investigating isatuximab, an anti-CD38 monoclonal antibody, plus bortezomib-lenalidomide-dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for transplant. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Ocio reveals that isatuximab plus VRd, followed by isatuximab plus Rd, is well tolerated, with few toxicities and high response rates.

Share this video